心肌炎与心包炎:免疫接种安全性数据收集、分析和呈现的病例定义与指南
本文为心肌炎和/或心包炎(MPC)作为免疫接种后不良事件(AEFI)的病例定义与数据收集指南。文件基于既往经验与全面文献综述制定,提出MPC的病例定义,并指出当前流行病学证据不支持疫苗与MPC存在因果关联,仅病例报告提供可能关联的证据。
要点
- 心肌炎和/或心包炎(MPC)是累及心肌和/或心包囊的炎症性疾病。
- MPC临床表现、病因和结局多样,包括急性心力衰竭、猝死和慢性扩张型心肌病。
- 当前流行病学证据不支持疫苗与MPC存在因果关联,仅病例报告提供可能关联证据。
核心结论
- 当前已发表的流行病学证据(相对风险较未接种背景发病率升高)不支持疫苗与MPC存在潜在因果关联。
- 唯一支持MPC与疫苗可能存在因果关联的证据来自病例报告。
研究设计与样本
- 本文为免疫接种安全性数据收集、分析和呈现的病例定义与指南。
- 病例定义基于既往经验与教训以及全面文献综述制定。
主要发现
- 心肌炎和/或心包炎(MPC)是累及心肌(伴非缺血性心肌细胞坏死)和/或心包囊的炎症性疾病。
- MPC最常见的病因为病毒性;非感染性、药物/疫苗相关过敏性和/或自身免疫性病因定义较不明确,炎症机制和治疗反应可能不同。
- 免疫接种后潜在心脏不良事件(AEFI)涵盖更广的诊断范围,如触发或加重缺血性心脏事件、伴潜在心力衰竭的心肌病、心律失常和猝死。
- 2006年CDC天花疫苗接种后不良事件定义中也定义了其他心脏不良事件,如扩张型心肌病。
- 多个团队已尝试制定并改进疫苗接种后心血管事件的定义和裁定。
关键数值与推荐
- 本文提出心肌炎和心包炎作为AEFI的当前病例定义。
- 其他病因和因果关系的考量不在本文档范围内。
临床怎么用
- 原文未据此给出推荐。
局限性
- 其他病因和因果关系的考量不在本文档范围内。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myocarditis and/or pericarditis (also known as myopericarditis) are inflammatory diseases involving the myocardium (with non-ischemic myocyte necrosis) and/or the pericardial sac. Myocarditis/pericarditis (MPC) may present with variable clinical signs, symptoms, etiologies and outcomes, including acute heart failure, sudden death, and chronic dilated cardiomyopathy. Possible undiagnosed and/or subclinical acute myocarditis, with undefined potential for delayed manifestations, presents further challenges for diagnosing an acute disease and may go undetected in the setting of infection as well as adverse drug/vaccine reactions. The most common causes of MPC are viral, with non-infectious, drug/vaccine associated hypersensitivity and/or autoimmune causes being less well defined and with potentially different inflammatory mechanisms and treatment responses. Potential cardiac adverse events following immunization (AEFIs) encompass a larger scope of diagnoses such as triggering or exacerbating ischemic cardiac events, cardiomyopathy with potential heart failure, arrhythmias and sudden death. The current published experience does not support a potential causal association with vaccines based on epidemiologic evidence of relative risk increases compared with background unvaccinated incidence. The only evidence supporting a possible causal association of MPC with a vaccine comes from case reports. Hypersensitivity MPC as a drug/vaccine induced cardiac adverse event has long been a concern for post-licensure safety surveillance, as well as safety data submission for licensure. Other cardiac adverse events, such as dilated cardiomyopathy, were also defined in the CDC definitions for adverse events after smallpox vaccination in 2006. In addition, several groups have attempted to develop and improve the definition and adjudication of post-vaccination cardiovascular events. We developed the current case definitions for myocarditis and pericarditis as an AEFI building on experience and lessons learnt, as well as a comprehensive literature review. Considerations of other etiologies and causal relationships are outside the scope of this document.
引用
- Sexson Tejtel SK, Munoz FM, Al-Ammouri I, et al. Myocarditis and pericarditis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2022. PMID: 35105494. doi:10.1016/j.vaccine.2021.11.074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。